Previous 10 | Next 10 |
Soligenix Receives $1.4M in Non-Dilutive Government Funding PR Newswire PRINCETON, N.J. , April 19, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commer...
Soligenix press release (NASDAQ:SNGX): FY GAAP EPS of -$0.31 misses by $0.01. Revenue of $0.8M (-66.7% Y/Y) beats by $0.08M. As of December 31, 2021, the Company's cash position was approximately $26.0M. For further details see: Soligenix GAAP EPS of -$0.31 misses by $0.01, revenue of $...
Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results PR Newswire PRINCETON, N.J. , March 29, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo...
Soligenix (NASDAQ:SNGX), a late-stage biopharmaceutical company, is trading ~9% higher in the pre-market Thursday after announcing data from a booster vaccination study based on its experimental COVID-19 vaccine CiVax involving non-human primates ((NHPs)). In reaction to a booster s...
Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron PR Newswire CiVax™ booster vaccine administered seven months after primary vaccination with COVID-19 adenovirus vaccine shows rapid enha...
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Their Specialized BioTherapeutics business segment is developing and moving toward potential commercialization ...
Investment Intended to Fuel Expansion for the World’s First Luxury Nomadic Hospitality Solution SG Blocks, Inc. (NASDAQ: SGBX) (“SG Blocks” or the “Company”), a leading developer, designer, and fabricator of modular structures, and Moliving...
Soligenix to Present at the Q1 Virtual Investor Summit PR Newswire PRINCETON, N.J. , March 2, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
Princeton, New Jersey--(Newsfile Corp. - March 1, 2022) - Soligenix, Inc. (NASDAQ: SNGX) today announced that Jonathan Guarino, Senior Vice President & Chief Financial Officer will be attending the Q1 Virtual Investor Summit. During the presentation, Soligenix’s Senior Vice Pres...
Soligenix to Present at the 2022 BIO CEO & Investor Conference Soligenix to Present at the 2022 BIO CEO & Investor Conference PR Newswire PRINCETON, N.J. , Feb. 8, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:20:00 ET July 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at biotech/biopharma stocks, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmaceutical compa...
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's ( Nasdaq:SNGX ) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte...